
Pediatrician

No OPD information available
Autism Spectrum Disorder
Fragile X Syndrome
Attention Deficit Hyperactivity Disorder (ADHD)
Obsessive-Compulsive Disorder (OCD)
Stereotypic Movement Disorder
Natalie Silove is a female professional who helps people with different conditions like Autism Spectrum Disorder, Fragile X Syndrome, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Disorder (OCD), and Stereotypic Movement Disorder.
Natalie Silove uses special skills and treatments to help her patients feel better. She listens carefully to what her patients say and works with them to find the best solutions. Patients trust Natalie because she is kind, understanding, and always ready to help.
To make sure she provides the best care, Natalie Silove stays updated with the latest medical knowledge and research. This helps her give the most effective treatments to her patients.
Natalie Silove works closely with other medical professionals to make sure her patients get the best care possible. She values teamwork and collaboration to ensure that her patients receive comprehensive and holistic treatment.
Natalie Silove's work has had a positive impact on many patients' lives. She has helped children attending their first neurodevelopmental assessment by identifying their strengths and developing a checklist to support them. Her dedication and expertise have made a difference in the lives of many individuals and families.
One of Natalie Silove's notable publications is a study on caregiver-identified strengths in children attending neurodevelopmental assessments. She also leads a clinical trial called "RECONNECT," which aims to study the efficacy and safety of a treatment for Fragile X Syndrome in children, adolescents, and young adults.
In summary, Natalie Silove is a caring and dedicated professional who uses her skills and knowledge to help individuals with various conditions. Her commitment to staying updated with the latest research and collaborating with other medical professionals ensures that her patients receive the best possible care.
Enrollment Status: Recruiting
Published: January 27, 2025
Intervention Type: Drug
Study Drug: ZYN002
Study Phase: Phase 3
